Relationship between Candida Species and use of Intrauterine Contraceptives Device in Women with Vulvovaginitis

Authors

  • Roaa Muhmmed Yahya
  • Bashar Sadeq Noomi
  • Hiba younis Khalaf

DOI:

https://doi.org/10.47750/pnr.2022.13.03.154

Keywords:

IUCD, Vulvovaginal exudate, candidiasis, age groups, VITEK 2.

Abstract

Background: The symptoms of candidiasis include vaginal discharge and itching. The severity of the patient's pain is linked to candidiasis. Isolated Candida species from vulvovaginal exudates to intrauterine contraceptive devices (IUDs) were evaluated.
Methods: Eighty samples of vaginal swabs taken from female patients at a maternity teaching hospital in Erbil City between May and November 2021 complained of vulvovaginitis symptoms, including both intrauterine contraceptive devices (IUCD) and non-intrauterine contraceptive users. The vaginal samples from patients were cultured on Sabouraud Dextrose Agar (SDA), and species identification utilizing an automated VITEK 2 compact system
Results: There are significant differences in the incidence of Candida infection between intrauterine contraceptive women (18.75%) with women who are not used intrauterine contraceptive methods (3.75%). The mean age was 30.67 ± 7.861 years. The highest incidence rate had discovered in the age group of 31-35years 10(32.26%), followed by 26-30 years 7(22.58%), and the lowest rate was observed in less than 20 years which was 2(6.45%). All Candida isolates from positive samples were identified by using Sabouraud Dextrose Agar and a confirmed automated VITEK 2 compact system. The identified Candida spp. was C. albicans 18 (22.5%), C.krusei 7(8.75%), then C. spherica 6(7.5%).
Conclusion: The incidence of vulvovaginal candidiasis and the use of contraceptives are clearly correlated, with C.albicans being the most common species.

Downloads

Published

2022-10-03

Issue

Section

Articles

How to Cite

Relationship between Candida Species and use of Intrauterine Contraceptives Device in Women with Vulvovaginitis. (2022). Journal of Pharmaceutical Negative Results, 13(3), 989-993. https://doi.org/10.47750/pnr.2022.13.03.154